Skip to main content
ENGN logo

ENGN · enGene Therapeutics Inc.

Track ENGN — free
$1.74 -0.02 (-1.14%) At close · Nov 20
Market Cap
$116.61M
Shares
67.02M
Volume · Nov 20 556.73K Avg daily vol (3M) 1.1M

Price & Indicators

 

Key stats

Close
$1.74
Fri 20 Nov
Open
$1.75
Fri 20 Nov
Average volume, 30 days
1.5M
shares a session
Short interest
1.6M
2.4% of shares · 1.9 days to cover
Day range
$1.69$1.80
Open $1.75 Close $1.74
52-week closing range
$1.44$12.17
Close $1.74 85.7% under the high
Short volume, last session
50%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Sep 8
Price history
Feb 2022 to Nov 2026

Latest documents

2026
Nov 19
Investor event
BLA filing due by year-end, approval targeted by end of 2027

NGene Therapeutics plans to file its BLA for its lead bladder cancer therapy by the end of this year, with approval expected by the end of 2027. The FDA agreed on key statistical analysis plan points that will cut the label database from 125 patients to 120. The company reported $246 million in cash.

7 source passages
I'd like to welcome Ron Cooper, the CEO of NGene Therapeutics. We plan to initiate the filing by the end of this year, the BLA. Approval by the end of 2027. We got agreement with the FDA on the most important aspects of the statistical analysis plan. we had 125 patients that were in the study. So the database that will form our label will be, when we submit it, will be 120 patients. We're sitting with $246 million cash, enough money to do all that and more. Open the document at this passage
Nov 16
Investor event
Bladder cancer therapy BLA planned by year-end, approval expected 2027

enGene's non-viral gene therapy for bladder cancer lifted its complete response rate from 54% to 56%. It plans to file a BLA by the end of this year and expects approval in 2027.

3 source passages
The dental imaging CR rate moved from 54% to 56%, which puts it right in the middle of the range of approved products. this is an asset that we plan to file the BLA by the end of this year, and we're going to expect an approval next year. We anticipate initiating the filing this year, and we expect an approval in 2027. Open the document at this passage
Nov 12
Current report 8-K Events of Nov 11
Detalimogene Achieves 56% Complete Response Rate

enGene Therapeutics Inc. reported 56% complete response at any time for detalimogene in Cohort 1 of Phase 2 LEGEND, with 43% Kaplan-Meier estimated duration of response of at least 12 months and plans to initiate BLA filing in 4Q 2026.

Financial results, Regulation FD disclosure, Other events Read from the first part of this long document
5 source passages
enGene Therapeutics Inc. (the “Company”) updated its Corporate Presentation and its Investor Presentation On November 11, 2026, the Company announced results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene, and alignment with the FDA on key components of the planned Biologics License Application. CR Rate, % (95% CI) Complete Response at Any Time Oct 2026 (n=120) 56% (CI: 47%, 65%) Duration of Response ≥ 12 months (KM) 43% (CI: 30%, 55%) 4Q 2026 Initiate BLA Filing; 2027 Potential BLA Approval; Detalimogene + Surfactant Data Mid 2027 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$130.36M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.7
Trailing earnings · reciprocal yield 139.7%
FCF yield
-89.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$240.97M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.5%
Year over year · more shares
Price change (1Y)
-73.6%
Trailing year
Short interest
2.4%
Latest settlement · 1.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −54%
below
Price vs 50-day avg −3%
below
RSI (14) 49
neutral
MACD trend Positive
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +12%
trailing
6-month return 0%
trailing
YTD return −81%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +14 funds added
Insider flow Accumulating
Net +$10.1K over 90 days · 0% sells
Short interest Rising
2.42% of shares out · ▲ +8.1% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
68 holders — near 3-yr high, broad support
Squeeze score 50
elevated · 0–100
Fundamentals
Strong
EPS growth +57%
Y/Y
Free cash flow $-100.7M
Balance sheet $26.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 114%
annualized · 1-yr
Max drawdown −88%
past year
ATR 10.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jun 15, 2026
second half of 2026
Restructuring costs $5.7M – $6.4M
Non-cash stock-based compensation expense $4.7M – $5M
upon achievement of milestones in 2026 and 2027
Aggregate cash retention bonus awards $1.7M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−54% Bearish
Price vs 50-day avg
−3% Neutral
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +14 funds added
Insider flow Accumulating
Net +$10.1K over 90 days · 0% sells
Short interest Rising
2.42% of shares out · ▲ +8.1% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
68 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 3% Range high $12
vs 200-day avg -54% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Addressable NMIBC BCG-unresponsive patients 20,000 November 2026 —
Bladder Cancer Urologists 11,000 November 2026 —
Bladder spasm 13% as of 29 October 2026 —
CR at any time 56% October 29, 2026 —
CRs occurred at first assessment 91% 29 October 2026 —
Discontinuation 1% 29 October 2026 —
Dose Interruption 4% 29 October 2026 —
Dysuria 16% as of 29 October 2026 —
EE patients remain free from cystectomy 86% 29 October 2026 —
EE patients were free from progression to ≥T2 disease 97% 29 October 2026 —
efficacy-evaluable patients enrolled in Cohort 1 120 October 29, 2026 —
Fatigue 21% as of 29 October 2026 —
Landmark 12-month CR rate 24% October 29, 2026 —
Median duration of complete response 10.1 October 29, 2026 —
Median follow-up for responders 12 October 29, 2026 —
Median follow-up of all EE Population patients 7.5 29 October 2026 —
Micturition urgency 13% as of 29 October 2026 —
Of those with TRAEs, percent that were Grade 1-2 93% 29 October 2026 —
patients assessed for safety in Cohort 1 125 October 29, 2026 —
patients enrolled in Cohort 1 125 October 29, 2026 —
patients experiencing a serious TRAE 2% October 29, 2026 —
patients experiencing at least one TRAE 59% October 29, 2026 —
patients experiencing Grade 3 TRAE 4% October 29, 2026 —
Patients in community practices 75% November 2026 —
Pollakiuria 16% as of 29 October 2026 —
Practicing Urologists 14,600 November 2026 —
Preliminary Kaplan-Meier Estimate of DoR ≥12 months 43% October 29, 2026 —
Responders remain free from cystectomy 96% 29 October 2026 —
Responders were free from progression to ≥T2 disease in the bladder 100% 29 October 2026 —
treat bladder cancer 75% as of 29October2026 —
Urinary tract infection 10% as of 29 October 2026 —
Cash, cash equivalents and marketable securities $266.3M As of July 31, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ENGN
enGene Therapeutics Inc.
this stock
$116.61M -80.7% — — 2.4%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
68
% held
75.8%
Net QoQ
-1.7M sh
Top holder
FCPM III SERVICES B.V.
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
1.6M
Days to cover
1.9d
Change
+121.4K sh
View
Short Volume
Short vol %
50%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
9.1K
Value
$14.3K
As of
Oct 15, 2026
View
Off-Exchange
Off-exchange %
50.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$10.1K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-117.3M
EPS diluted
$2.29
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 19, 2026
This year
26

NGene Therapeutics plans to file its BLA for its lead bladder cancer therapy by the end of this year, with approval expected by the end of 2027. The FDA agreed on key statistical analysis plan points that will cut the label database from 125 patients to 120. The company reported $246 million in cash.

View
Earnings & Events
Webcasts
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
enGene to Initiate a BLA Submissi…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
ENGN -27.8% +11.5% +0.0% +13.7% -80.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -19.2% +20.8% +9.2% +22.5% -81.9%
Key facts CIK 1980845 CUSIP 29286X101 13F (30d) 59 filings 58 filers Visit website Investor relations